Form 4: AYTU BioPharma CCO Receives Restricted Stock Grant

AYTU BioPharma's Chief Commercial Officer, Greg Pyszczymuka, was granted 12,500 shares of restricted common stock.

Summary

• Greg Pyszczymuka, Chief Commercial Officer of AYTU BioPharma, Inc. (AYTU), acquired 12,500 shares of common stock on October 3, 2025.
• The acquisition was a grant of restricted stock with a price of $0 per share.
• Following this transaction, Mr. Pyszczymuka directly beneficially owns 36,102 shares of common stock.
• The restricted stock vests in a staggered schedule: one-third on October 3, 2026, and the remaining portion in eight equal quarterly installments starting January 3, 2027.
• A Limited Power of Attorney was granted by Greg Pyszczymuka on September 17, 2025, authorizing specific individuals to execute and file Section 16(a) reports on his behalf.

Sentiment

Score: 7

Explanation: The grant of restricted stock to a key executive is generally a positive event, indicating executive retention and alignment with shareholder interests. The $0 price reflects it as compensation rather than a purchase.

Positives

• The grant of 12,500 restricted shares aligns the Chief Commercial Officer's interests with those of shareholders.
• The vesting schedule provides an incentive for long-term performance and retention of a key executive.

Negatives

• No specific negative aspects were identified within the scope of this Form 4 filing.

Risks

• No specific risks were mentioned in this Form 4 filing, which primarily reports an insider transaction.

Future Outlook

The restricted stock grant includes a future vesting schedule, with one-third vesting on October 3, 2026, and the remainder vesting quarterly starting January 3, 2027, indicating a long-term incentive structure for the Chief Commercial Officer.

Industry Context

This filing reports a standard equity compensation event for a key executive in a publicly traded biopharmaceutical company. Such grants are common practice to incentivize and retain talent within the competitive biotech and pharma sectors.

Comparison to Industry Standards

• The grant of restricted stock to a Chief Commercial Officer is a common form of executive compensation in the biopharmaceutical industry, aligning executive interests with long-term company performance.
• The vesting schedule, with an initial one-year cliff and subsequent quarterly installments, is typical for executive equity awards, similar to practices observed at companies like Moderna (MRNA) or Pfizer (PFE) for their senior leadership, though the specific amounts and schedules vary by company size and executive role.

Corporate Governance

Related Party Transactions

• The restricted stock grant to Greg Pyszczymuka, an officer of AYTU BioPharma, is a transaction between the company and a related party (executive compensation).

Stakeholder Impact

• **Shareholders**: The grant aligns the Chief Commercial Officer's long-term interests with shareholder value creation, though it represents a minor dilution.
• **Employees**: Reflects standard executive compensation practices, potentially influencing overall compensation philosophy.
• **Management**: Strengthens the Chief Commercial Officer's commitment and incentivizes performance through equity ownership.

Next Steps

• One-third of the restricted stock will vest on October 3, 2026.
• The remaining restricted stock will vest in eight equal quarterly installments beginning January 3, 2027.

Key Dates

Keywords

AYTU BioPharma, AYTU, Greg Pyszczymuka, Chief Commercial Officer, Restricted Stock Grant, Insider Transaction, Equity Compensation, SEC Form 4, Stock Vesting